MOLECULAR MARKERS FOR CANCER PROGNOSIS
    1.
    发明申请
    MOLECULAR MARKERS FOR CANCER PROGNOSIS 审中-公开
    癌症预防分子标记

    公开(公告)号:US20110172928A1

    公开(公告)日:2011-07-14

    申请号:US12999406

    申请日:2009-06-16

    IPC分类号: G06F19/00

    摘要: The present invention relates to methods for prediction of an outcome of neoplastic disease or cancer. More specifically, the present invention relates to a method for the prediction of breast cancer by determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CA12, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF.

    摘要翻译: 本发明涉及用于预测肿瘤性疾病或癌症的结果的方法。 更具体地,本发明涉及通过在来自所述患者的生物样品中测定多种选自ACTG1,CA12,CALM2,CCND1,CHPT1,CLEC2B的多种基因的表达水平来预测乳腺癌的方法 ,CTSB,CXCL13,DCN,DHRS2,EIF4B,ERBB2,ESR1,FBXO28,GABRP,GAPDH,H2AFZ,IGFBP3,IGHG1,IGKC,KCTD3,KIAA0101,KRT17,MLPH,MMP1,NAT1,NEK2,NR2F2,OAZ1,PCNA,PDLIM5 ,PGR,PPIA,PRC1,RACGAP1,RPL37A,SOX4,TOP2A,UBE2C和VEGF。

    ALGORITHMS FOR OUTCOME PREDICTION IN PATIENTS WITH NODE-POSITIVE CHEMOTHERAPY-TREATED BREAST CANCER
    2.
    发明申请
    ALGORITHMS FOR OUTCOME PREDICTION IN PATIENTS WITH NODE-POSITIVE CHEMOTHERAPY-TREATED BREAST CANCER 审中-公开
    患有结直肠癌治疗乳腺癌的患者的预后预测方法

    公开(公告)号:US20110166838A1

    公开(公告)日:2011-07-07

    申请号:US12999522

    申请日:2009-06-16

    IPC分类号: G06F7/60

    摘要: The invention relates to methods for predicting an outcome of cancer in a patient suffering from cancer, said patient having been previously diagnosed as node positive and treated with cytotoxic chemotherapy, said method comprising determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CAl2, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF; ABCB1, ABCG2, ADAM15, AKR1C1, AKR1C3, AKT1, BANF1, BCL2, BIRC5, BRMS1, CASP10, CCNE2, CENPJ, CHPT1, EGFR, CTTN, ERBB3, ERBB4, FBLN1, FIP1L1, FLT1, FLT4, FNTA, GATA3, GSTP1, Herstatin, IGF1R, IGHM, KDR, KIT, CKRT5, SLC39A6, MAPK3, MAPT, MKI67, MMP7, MTA1, FRAP1, MUC1, MYC, NCOA3, NFIB, OLFM1, TP53, PCNA, PI3K, PPERLD1, RAB31, RAD54B, RAF1, SCUBE2, STAU, TINF2, TMSL8, VGLL1, TRA@, TUBA1, TUBB, TUBB2A.

    摘要翻译: 本发明涉及用于预测患有癌症的患者的癌症结果的方法,所述患者先前被诊断为淋巴结阳性并用细胞毒性化疗治疗,所述方法包括在来自所述患者的生物样品中确定多个表达水平 选自ACTG1,CA2,CALM2,CCND1,CHPT1,CLEC2B,CTSB,CXCL13,DCN,DHRS2,EIF4B,ERBB2,ESR1,FBXO28,GABRP,GAPDH,H2AFZ,IGFBP3,IGHG1,IGKC,KCTD3, KIAA0101,KRT17,MLPH,MMP1,NAT1,NEK2,NR2F2,OAZ1,PCNA,PDLIM5,PGR,PPIA,PRC1,RACGAP1,RPL37A,SOX4,TOP2A,UBE2C和VEGF; ABCB1,ABCG2,ADAM15,AKR1C1,AKR1C3,AKT1,BANF1,BCL2,BIRC5,BRMS1,CASP10,CCNE2,CENPJ,CHPT1,EGFR,CTTN,ERBB3,ERBB4,FBLN1,FIP1L1,FLT1,FLT4,FNTA,GATA3,GSTP1, Herbatin,IGF1R,IGHM,KDR,KIT,CKRT5,SLC39A6,MAPK3,MAPT,MKI67,MMP7,MTA1,FRAP1,MUC1,MYC,NCOA3,NFIB,OLFM1,TP53,PCNA,PI3K,PPERLD1,RAB31,RAD54B,RAF1, SCUBE2,STAU,TINF2,TMSL8,VGLL1,TRA @,TUBA1,TUBB,TUBB2A。

    Method for identifying predictive biomarkers from patient data
    4.
    发明授权
    Method for identifying predictive biomarkers from patient data 失效
    从患者数据中识别预测性生物标志物的方法

    公开(公告)号:US08355874B2

    公开(公告)日:2013-01-15

    申请号:US12158744

    申请日:2006-12-11

    IPC分类号: G01N33/48

    CPC分类号: G06F19/18 G06Q50/24

    摘要: The invention relates to a method for developing a biomarker for the prognosis of the result of a therapeutical treatment based on data obtained in clinical studies, data remaining unchanged by therapy being subdivided into diagnostic and genomic parameters and the marker being defined by a combination of parameters. The method according to the invention is characterized by specifying the maximum number of parameters for defining the marker and thus the maximum complexity of the system from the beginning and by carrying out the search for defining parameters by sequential combination of clinical parameters (=z parameters) and/or genomic parameters (=x parameters).

    摘要翻译: 本发明涉及一种基于临床研究中获得的数据,用于预测治疗结果预后的生物标志物的方法,通过治疗将其保持不变的数据被细分为诊断和基因组参数,并且所述标记由参数组合定义 。 根据本发明的方法的特征在于指定用于定义标记的参数的最大数目,并且因此指定从一开始的系统的最大复杂度,并且通过临时参数(= z参数)的顺序组合执行定义参数的搜索, 和/或基因组参数(= x参数)。

    METHOD FOR THE QUALITY ASSESSMENT OF NUCLEIC ACID AMPLIFICATION REACTIONS
    5.
    发明申请
    METHOD FOR THE QUALITY ASSESSMENT OF NUCLEIC ACID AMPLIFICATION REACTIONS 审中-公开
    核酸扩增反应质量评估方法

    公开(公告)号:US20110166845A1

    公开(公告)日:2011-07-07

    申请号:US13061797

    申请日:2009-07-16

    IPC分类号: G06G7/58

    摘要: The invention relates to a method for the quality assessment of nucleic acid amplification reactions which is based on a mathematical approach for the quality assessment of complete nucleic acid amplification reactions and comprises the following steps: a) Carrying out an amplification reaction for at least one nucleic acid target molecule, b)Collecting time-related data reflecting the course of the amplification reaction, c) Fitting these time-related data with a growth model equation comprising at least one parameter, d) Obtaining, from said fitting process, at least one value for the at least one parameter.

    摘要翻译: 本发明涉及一种核酸扩增反应质量评估方法,该方法基于完整核酸扩增反应的质量评估的数学方法,包括以下步骤:a)对至少一个核酸进行扩增反应 酸性靶分子,b)收集反映扩增反应过程的时间相关数据,c)使用包含至少一个参数的生长模型方程拟合这些时间相关数据,d)从所述拟合过程获得至少一个 至少一个参数的值。

    Prediction of Breast Cancer Response to Taxane-Based Chemotherapy
    6.
    发明申请
    Prediction of Breast Cancer Response to Taxane-Based Chemotherapy 审中-公开
    预测基于紫杉烷的化疗的乳腺癌反应

    公开(公告)号:US20090239223A1

    公开(公告)日:2009-09-24

    申请号:US12307590

    申请日:2007-07-06

    IPC分类号: C12Q1/68

    摘要: The invention relates to methods and kits for the prediction of a likely outcome of chemotherapy in a cancer patient. More specifically, the invention relates to the prediction of tumour response to chemotherapy based on measurements of expression levels of a small set of marker genes. The set of marker genes is useful for the identification of breast cancer subtypes responsive to taxane based chemotherapy, such as e.g. a taxane-anthracycline-cyclophosphamide-based (e.g. Taxotere (docetaxel)-Adriamycin (doxorubicin)-cyclophosphamide, i.e. (TAC)-based) chemotherapy.

    摘要翻译: 本发明涉及用于预测癌症患者化学疗法可能结果的方法和试剂盒。 更具体地,本发明涉及基于对一小组标记基因的表达水平的测量来预测肿瘤对化学疗法的反应。 该组标记基因可用于鉴定对基于紫杉烷的化学疗法有效的乳腺癌亚型,例如, 紫杉烷 - 蒽环类 - 环磷酰胺(如泰索帝(多西紫杉醇) - 阿霉素(多柔比星) - 环磷酰胺,即(TAC))化疗。

    Diagnosis, Prognosis and Prediction of Recurrence of Breat Cancer
    7.
    发明申请
    Diagnosis, Prognosis and Prediction of Recurrence of Breat Cancer 审中-公开
    诊断,预后和预测的复发性肺癌

    公开(公告)号:US20090222387A1

    公开(公告)日:2009-09-03

    申请号:US11922276

    申请日:2006-06-14

    IPC分类号: G06F15/18

    CPC分类号: G16B40/00 G16B25/00

    摘要: The present invention relates to methods and compositions for the diagnosis, prognosis, and prediction of breast cancer. More specifically, the invention relates to classification of breast cancer tissue samples based on measuring the expression of a set of marker genes. The set is useful for the identification of clinically important breast cancer subtypes. Methods are disclosed for prediction, diagnosis and prognosis of breast cancer.

    摘要翻译: 本发明涉及用于乳腺癌诊断,预后和预测的方法和组合物。 更具体地,本发明涉及基于测量一组标记基因的表达的乳腺癌组织样品的分类。 该组对于鉴定临床重要的乳腺癌亚型是有用的。 公开了乳腺癌预测,诊断和预后的方法。